ARL17A (ADP-ribosylation factor-like GTPase 17A) and its fusion with KANSL1 has previously been seen within a cohort of patients with relapsing malignancies and is predicted to predispose a patient to cancer as it is linked to histone acetylation, but it has not yet been associated directly with prostate cancer [79]. Here, ARL17A is linked to prostate carcinoma.